The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
Texas MPN Workshop 2021 | Recent updates in the field of polycythemia vera
Prithviraj Bose, MBBS, MD Anderson Cancer Center, Houston, TX, discusses recent and upcoming updates in the field of polycythemia vera. Dr Bose highlights the use of ropeginterferon alfa-2b, an agent which has already received approval in Europe, and rusfertide, a hepcidin mimetic shown to reduce the need for phlebotomy. Ropeginterferon alfa-2b approval was based on the results of the Phase II PROUD-PV (NCT01949805) and CONTI-PV (NCT02218047) trials. This interview took place at the Texas MPN Workshop: Second Annual Workshop and Meeting in 2021.
Disclosures
Prithviraj Bose, MBBS, has received honoraria from Incyte, Celgene, BMS, CTI BioPharma, Sierra Oncology, Novartis, Blueprint Medicines and Kartos; and has received research support from Incyte, Celgene, BMS, CTI BioPharma, Constellation, Kartos, Blueprint Medicines, Astellas, Pfizer, Promedior and NS Pharma.
